Gauging the accuracy of breast cancer biomarker tests

November 1, 2012

A team led by David Rimm, professor of pathology at Yale School of Medicine, investigated protein expression in breast tissue biomarkers to determine whether the time from tissue removal to fixation in preservative can affect the accuracy of testing for cancer.

The study appears in the Journal of the .

An inaccurate measurement can result in false-negative results.

The researchers found significant changes in several of the proteins, and recommend that more testing be done to ensure accurate assessment of tissue biomarkers for the presence of cancer.

Explore further: False negative tests in breast cancer may lead to wrong drug choice

More information: Read the study: jnci.oxfordjournals.org/conten … /18/jnci.djs438.full

Related Stories

False negative tests in breast cancer may lead to wrong drug choice

June 27, 2011
A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified ...

Addressing high false-positive rates for mammograms

June 13, 2011
We've heard it repeatedly: early detection is key to surviving breast cancer. But even with recent advances in mammography, finding indications of breast cancer before it can metastasize remains a problem. Scientists at Pacific ...

Singling out the real breast cancer among the lumps

October 25, 2011
(Medical Xpress) -- Early detection of breast cancer saves thousands of lives each year. But screening for breast cancer also produces false alarms, which can cause undue stress and costly medical bills. Now, a recent study ...

Recommended for you

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.